+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID07264075

Phase 3 Study Comparing Ivonescimab Alone or With Ligufalimab to Pembrolizumab for First-line Treatment of Recurrent or Metastatic PD-L1-Positive Head and Neck Squamous Cell Carcinoma

Led by Groupe Oncologie Radiotherapie Tete et Cou · Updated on 2026-05-20

780

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of ivonescimab alone or combined with ligufalimab compared to pembrolizumab as a first treatment for patients with recurrent or metastatic PD-L1-positive squamous cell carcinoma of the head and neck HNSCC. This phase 3 study aims to improve overall survival for patients with this condition, focusing on those with a Combined Positive Score CPS of 1 or higher. Participants will be randomly assigned to one of three treatment groups ivonescimab alone, ivonescimab combined with ligufalimab, or pembrolizumab. Ivonescimab is given intravenously at 10 mgkg over about 60 minutes every three weeks. The combination group receives ivonescimab at the same dose and schedule along with ligufalimab at 45 mgkg over about 120 minutes every three weeks. The pembrolizumab group receives 200 mg intravenously every three weeks. Treatments continue up to 24 months or until disease progression, intolerable side effects, death, or other specific reasons for stopping. During the study, participants will be regularly monitored through clinical assessments and laboratory tests to track treatment effects, side effects, and overall health. The primary outcome measured is overall survival from randomization up to 54 months. Researchers will also check organ function and cancer status. The total length of participation may last until treatment completion or earlier if needed, with ongoing safety monitoring throughout the study.

CONDITIONS

Brief Title

Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here